|
|
Volumn 343, Issue 7830, 2011, Pages
|
|
Cost of dabigatran for atrial fibrillation
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICOAGULANT AGENT;
ANTIVITAMIN K;
DABIGATRAN;
DABIGATRAN ETEXILATE;
PROTON PUMP INHIBITOR;
WARFARIN;
AGING;
BLEEDING;
BRAIN HEMORRHAGE;
CATHETER ABLATION;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
DISEASE ASSOCIATION;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG MECHANISM;
DRUG MONITORING;
DRUG SAFETY;
DYSPEPSIA;
EDITORIAL;
HEALTH CARE COST;
HEART ATRIUM FIBRILLATION;
HEART INFARCTION;
HIGH RISK PATIENT;
HUMAN;
INTERNATIONAL NORMALIZED RATIO;
OBESITY;
PATIENT COMPLIANCE;
PATIENT PREFERENCE;
PATIENT SELECTION;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RISK BENEFIT ANALYSIS;
STROKE;
ANTICOAGULANTS;
ANTITHROMBINS;
ATRIAL FIBRILLATION;
BENZIMIDAZOLES;
FEMALE;
HUMANS;
MALE;
PYRIDINES;
WARFARIN;
|
|
EID: 84858999519
PISSN: 09598146
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.d6980 Document Type: Editorial |
|
Times cited : (8)
|
|
References (8)
|
